1.0Public Citizenhttps://www.citizen.orgDiane Krauthamerhttps://www.citizen.org/author/dkrauthamer/Testimony on Fluticasone/Vilanterol Combination Therapy to the FDA's Pulmonary-Allergy Drugs Advisory Committee - Public Citizenrich600338<blockquote class="wp-embedded-content" data-secret="nKiZw4OURp"><a href="https://www.citizen.org/article/testimony-on-fluticasone-vilanterol-combination-therapy-to-the-fdas-pulmonary-allergy-drugs-advisory-committee/">Testimony on Fluticasone/Vilanterol Combination Therapy to the FDA’s Pulmonary-Allergy Drugs Advisory Committee</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/testimony-on-fluticasone-vilanterol-combination-therapy-to-the-fdas-pulmonary-allergy-drugs-advisory-committee/embed/#?secret=nKiZw4OURp" width="600" height="338" title="“Testimony on Fluticasone/Vilanterol Combination Therapy to the FDA’s Pulmonary-Allergy Drugs Advisory Committee” — Public Citizen" data-secret="nKiZw4OURp" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
The Food and Drug Administration (FDA) should not approve the proposed combination therapy, fluticasone/vilanterol (proposed trade name: Breo Ellipta) for the treatment of chronic obstructive pulmonary disease (COPD), because the drug is largely ineffective and causes serious side effects compared with vilanterol given alone, and was studied in a series of unethical clinical trials.https://www.citizen.org/wp-content/uploads/public_citizen_shared_link.jpg1200628